rosiglitazone has been researched along with Fatty Liver, Nonalcoholic in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 30 (76.92) | 24.3611 |
| 2020's | 9 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, L; Chen, T; Chen, Z; Ding, Y; Li, S; Lin, L; Ma, L; Peng, A; Qiu, N; Wang, G; Wei, Y; Xu, Q; Yang, J; Ye, X; Zheng, H | 1 |
| Chen, J; Chen, L; Huang, L; Lai, H; Liang, X; Liu, J; Ma, L; Pei, H; Peng, A; Ran, Y; Sang, Y; Wei, Y; Xiang, M; Xie, C | 1 |
| Amaudrut, J; Barth, M; Binet, J; Boubia, B; Broqua, P; Chatar, M; Dodey, P; Ferry, S; Gauthier, E; Guillier, F; Jacquier, E; Junien, JL; Lacombe, O; Legendre, C; Lepais, V; Llacer, J; Luccarini, JM; Masson, P; Montalbetti, C; Mounier, L; Peralba, P; Poupardin, O; Thourigny, A; Wettstein, G | 1 |
| Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
| Cai, Z; Deng, L; Geng, X; Hu, L; Jiao, S; Li, Z; Ren, Q; Wang, B; Yang, Y; Zhang, L; Zhou, Z | 1 |
| Shu, S; Wang, H; Wang, Q; Xu, Z | 1 |
| Bhaskar, AK; Sachidanandan, C; Sengupta, S; Singh, MK; Yadav, R | 1 |
| Newman, EM; Rowland, A | 1 |
| Alexopoulos, SJ; Beretta, M; Byrne, FL; Cantley, J; Chen, SY; Garcia, CJ; Hoehn, KL; Larance, M; Olzomer, EM; Philp, A; Salamoun, JM; Santos, WL; Shah, DP; Smith, GC; Turner, N | 1 |
| Blazina, I; Selph, S | 1 |
| Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A | 1 |
| Cordoba-Chacon, J; De Jesus, A; Diaz-Ruiz, A; Guzman, G; Layden, BT; Lee, SM; Muratalla, J; Norris, GH; Pusec, CM; Sarmento-Cabral, A | 1 |
| Cordoba-Chacon, J; Diaz-Ruiz, A; Kineman, RD; Lee, SM; Liew, CW; McCann, M; Muratalla, J; Remon-Ruiz, P | 1 |
| Hu, A; Hu, Y; Li, D; Li, H; Ying, H | 1 |
| Azhar, S; Bittner, S; Han, L; Kraemer, FB; Shen, WJ | 1 |
| Akkoc, H; Akkus, M; Kelle, I; Topal, AE; Yilmaz, S | 1 |
| Bi, J; Chen, X; Mao, J; Sun, K; Tang, H; Wu, H | 1 |
| Arteel, GE; Chartoumpekis, DV; Fazzari, M; Freeman, BA; Guimaraes, DA; Khoo, NKH; Li, L; Shiva, S | 1 |
| Ackerman, Z; Ben-Ari, Z; Chepurko, Y; Cohen, M; Grossman, E; Hochhauser, E; Leibowitz, A; Schmilovitz-Weiss, H; Yitzhaki, S | 1 |
| Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A | 1 |
| Gu, YE; Liu, XC; Yao, Z | 1 |
| Åberg, F; Arola, J; Boyd, S; Isoniemi, H; Koljonen, V; Nikkilä, K | 1 |
| Herrigel, DJ; Moss, RA | 1 |
| Allen, AM; Khera, R; Loomba, R; Murad, MH; Singh, S | 1 |
| Cui, Y; Deng, M; Qi, ZG; Shang, X; Wang, XL; Xie, ML; Xue, J; Zhang, Y; Zhao, X | 1 |
| Alsaggar, M; Gao, M; Liu, D; Ma, Y | 1 |
| Batatinha, HA; Biondo, LA; Lima, EA; Lira, FS; Rosa Neto, JC; Silveira, LS; Souza, CO; Teixeira, AA | 1 |
| Chandrasekaran, S; Khan, AA; Krishnan, UM; Kulkarni, NM; Mahat, MY; Malampati, S; Narayanan, S; Raghul, J | 1 |
| Kleemann, R; Kooistra, T; Liang, W; Morrison, MC; Mulder, P; van Bockel, JH; Verschuren, L; Wielinga, PY | 1 |
| Aslanidis, C; Buechler, C; Eisinger, K; Haberl, EM; Krautbauer, S; Neumann, M; Pohl, R; Rein-Fischboeck, L; Schacherer, D; Weiss, TS; Zimny, S | 1 |
| Chen, Q; Liu, B; Liu, S; Wu, HJ; Wu, JP; Zhang, ZQ; Zhu, L | 1 |
| Białkowska, J; Borkowska, A; Czupryniak, L; Ignaczak, A; Jabłkowski, M; Kwiecińska, E; Loba, J; Omulecka, A; Pawłowski, M; Saryusz-Wolska, M; Szymańska-Garbacz, E | 1 |
| Harrison, SA; Jones, FJ; Shaw, JC; Torres, DM; Ward, JA; Williams, CD | 1 |
| Minhu, C; Yao, J; Zhi, M | 1 |
| Chalasani, N; Corey, KE | 1 |
| Kamal, MA; Qu, X; Seale, JP; Sun, LQ; Tan, Y; Wang, X | 1 |
| Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N | 1 |
| Aguila, MB; Fraulob, JC; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
| Baumann, U; Bhathal, PS; Brown, RM; Brunt, EM; Clouston, AD; Couper, RT; Dixon, JB; Ee, LC; Jonsson, JR; Manton, ND; Moschen, AR; Neuschwander-Tetri, BA; O'Brien, PE; Powell, EE; Richardson, MM; Skoien, R; Tilg, H; Weltman, M | 1 |
8 review(s) available for rosiglitazone and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure.
Topics: Animals; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Dextromethorphan; Metoprolol; Midazolam; Non-alcoholic Fatty Liver Disease; Omeprazole; Rosiglitazone; Warfarin | 2022 |
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Topics: Blood Glucose; Body Weight; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone | 2019 |
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Pioglitazone; PPAR delta; PPAR gamma; PPAR-beta; Rosiglitazone; Thiazolidinediones | 2017 |
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hypoglycemic Agents; Insulin; Liver Neoplasms; Metformin; Non-alcoholic Fatty Liver Disease; Pancreatic Neoplasms; Pioglitazone; Precancerous Conditions; Receptors, Somatomedin; Risk Factors; Rosiglitazone; Thiazolidinediones | 2014 |
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
Topics: Chenodeoxycholic Acid; Drug Therapy, Combination; Humans; Non-alcoholic Fatty Liver Disease; Pioglitazone; Publication Bias; Rosiglitazone; Thiazolidinediones; Vitamin E | 2015 |
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Review Literature as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2011 |
3 trial(s) available for rosiglitazone and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Danshao Shugan Granule therapy for non-alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cholesterol; Humans; Liver; Malondialdehyde; Medicine, Chinese Traditional; Mice; NF-kappa B; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Rosiglitazone; Silybin; Superoxide Dismutase; Triglycerides | 2022 |
Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease.
Topics: Adult; Case-Control Studies; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biopsy; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Losartan; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2011 |
28 other study(ies) available for rosiglitazone and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiponectin; Animals; Barbiturates; Cell Differentiation; Disease Models, Animal; Fatty Liver; Leptin; Male; Mice; Molecular Structure; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship; Thiobarbiturates | 2011 |
Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Alanine Transaminase; Animals; Barbiturates; Body Weight; Cholesterol; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Female; Glucose; Glucose Tolerance Test; Hep G2 Cells; Humans; Insulin; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Piperidines; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Tissue Distribution; Triglycerides | 2012 |
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
Topics: Animals; Benzothiazoles; Carbon Tetrachloride Poisoning; Cell Line; Drug Discovery; Fibrosis; Hepatocytes; High-Throughput Screening Assays; Humans; Hypoglycemic Agents; Indoles; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides | 2018 |
Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.
Topics: Animals; Chenodeoxycholic Acid; Drug Discovery; Gene Expression Regulation; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Mice, Inbred C57BL; Mice, Inbred ICR; Models, Molecular; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Peroxisome Proliferator-Activated Receptors; Protein Binding; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2022 |
A diet-independent zebrafish model for NAFLD recapitulates patient lipid profiles and offers a system for small molecule screening.
Topics: Animals; Diet, High-Fat; Inflammation; Interleukin-6; Non-alcoholic Fatty Liver Disease; Rosiglitazone; Triglycerides; Zebrafish | 2023 |
Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
Topics: Animals; Caloric Restriction; Diabetes Mellitus, Type 2; Ethanolamine; Ethanolamines; Female; Mice; Niclosamide; Non-alcoholic Fatty Liver Disease; Obesity; Rosiglitazone | 2024 |
Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver.
Topics: Animals; Diet, High-Fat; Female; Hepatocytes; Hypoglycemic Agents; Inflammation; Male; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; PPAR gamma; Rosiglitazone | 2021 |
Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity.
Topics: Animals; Diet, High-Fat; Hepatocytes; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Rosiglitazone | 2021 |
Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation.
Topics: Animals; Body Weight; Diet, High-Fat; Fatty Acids; Gynostemma; Lipogenesis; Liver; Liver Function Tests; Male; Non-alcoholic Fatty Liver Disease; Organ Size; Oxidation-Reduction; Plant Extracts; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2017 |
Metformin HCl has curative effect on rebuilding of ventricular diastolic functions in high-fat-diet fed rats.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Liver; Male; Metformin; Myocardium; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Rosiglitazone; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
PPARγ alleviated hepatocyte steatosis through reducing SOCS3 by inhibiting JAK2/STAT3 pathway.
Topics: Animals; Cell Line; Culture Media, Conditioned; Hepatocytes; Insulin Resistance; Janus Kinase 2; Kupffer Cells; Non-alcoholic Fatty Liver Disease; PPAR gamma; Rats; Rosiglitazone; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Thiazolidinediones | 2018 |
Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis.
Topics: Adipose Tissue; Animals; Biomarkers; Blood Glucose; Body Weight; Diet, High-Fat; Disease Models, Animal; Glucose Intolerance; Hepatocytes; Lipid Metabolism; Male; Mice; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Obesity; Oleic Acids; Protective Agents; Rosiglitazone; Triglycerides | 2019 |
Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective.
Topics: Animals; Bezafibrate; Disease Models, Animal; Fatty Liver; Fructose; Gene Expression; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones | 2013 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones | 2014 |
Schisandra chinensis Baill, a Chinese medicinal herb, alleviates high-fat-diet-inducing non-alcoholic steatohepatitis in rats.
Topics: Animals; Cholesterol; Cholesterol, LDL; Diet, High-Fat; Dietary Fats; Drugs, Chinese Herbal; Fatty Liver; Liver; Male; Malondialdehyde; Non-alcoholic Fatty Liver Disease; Phytotherapy; Random Allocation; Rats; Rats, Wistar; Rosiglitazone; Schisandra; Superoxide Dismutase; Thiazolidinediones | 2014 |
Thiazolidinedione therapy versus lifestyle recommendation in the treatment of post-liver transplant graft steatosis.
Topics: Adult; Cohort Studies; Female; Finland; Humans; Hypoglycemic Agents; Life Style; Liver Transplantation; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2014 |
PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
Topics: Anilides; Animals; Chemokine CCL2; Cytokines; Disease Models, Animal; Fatty Acids, Nonesterified; Fenofibrate; Gene Expression Regulation; Glutathione; Indoles; Inflammation; Interleukin-6; Interleukin-8; Lipid Metabolism; Liver; Male; Malondialdehyde; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidative Stress; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2015 |
Dual Outcomes of Rosiglitazone Treatment on Fatty Liver.
Topics: Animals; Diet, High-Fat; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; PPAR gamma; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2016 |
Association Between Aerobic Exercise and Rosiglitazone Avoided the NAFLD and Liver Inflammation Exacerbated in PPAR-α Knockout Mice.
Topics: Animals; Body Weight; Disease Progression; Fasting; Inflammation; Lipids; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Organ Size; Phosphorylation; Physical Conditioning, Animal; PPAR alpha; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2017 |
Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; High Fructose Corn Syrup; Male; Mice; Non-alcoholic Fatty Liver Disease; Rosiglitazone; Thiazolidinediones | 2016 |
Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice.
Topics: Adipose Tissue, White; Animals; Inflammation; Male; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Receptors, LDL; Rosiglitazone; Thiazolidinediones | 2016 |
Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Case-Control Studies; Cell Line; Cells, Cultured; Chemokines; Comorbidity; Cytokines; Diabetes Mellitus, Type 2; Female; Fibroblast Growth Factors; Hep G2 Cells; Hepatic Stellate Cells; Hepatocytes; Hepcidins; Humans; Hydrocarbons, Fluorinated; Hypertension; Hypoglycemic Agents; In Vitro Techniques; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Leptin; Lipocalin-2; Liver; Liver X Receptors; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Severity of Illness Index; Sulfonamides; Thiazolidinediones; Waist-Hip Ratio; Young Adult | 2017 |
The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats.
Topics: Adiponectin; Adipose Tissue; Animals; Body Weight; Dietary Fats; Disease Models, Animal; Fatty Liver; Gene Expression Regulation; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Receptors, Adiponectin; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
Effect of silybin on high-fat-induced fatty liver in rats.
Topics: Animals; Antioxidants; Dietary Fats; Disease Models, Animal; Drug Evaluation, Preclinical; Fatty Liver; Homeostasis; Hypoglycemic Agents; Insulin Resistance; Lipid Peroxidation; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Silybin; Silymarin; Thiazolidinediones | 2011 |
Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
Topics: Fatty Liver; Female; Humans; Losartan; Male; Metformin; Non-alcoholic Fatty Liver Disease; Rosiglitazone; Thiazolidinediones | 2011 |
Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Fatty Liver; Glucose Transporter Type 4; Insulin; Insulin Resistance; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oligonucleotides, Antisense; Retinol-Binding Proteins, Plasma; Rosiglitazone; Thiazolidinediones; Transfection | 2011 |
Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet.
Topics: Adipokines; Adipose Tissue; Adiposity; Animals; Blood Glucose; Body Composition; Diet, High-Fat; Fatty Liver; Fluorobenzenes; Homeostasis; Insulin Resistance; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Pyrimidines; Resistin; Rosiglitazone; Rosuvastatin Calcium; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Thiazolidinediones; Triglycerides | 2012 |
Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways.
Topics: Adolescent; Adult; Age Factors; Australia; Bile Ducts, Intrahepatic; Biomarkers; Biopsy; Cell Proliferation; Child; Child, Preschool; Europe; Fatty Liver; Gastric Bypass; Humans; Immunohistochemistry; Keratin-7; Liver; Liver Cirrhosis; Missouri; Non-alcoholic Fatty Liver Disease; Risk Factors; Rosiglitazone; Stem Cells; Thiazolidinediones; Treatment Outcome | 2013 |